Childhood Epilepsy Syndromes: Age-Specific Features and Management
The provided evidence focuses predominantly on neonatal seizures rather than broader childhood epilepsy syndromes, but I will synthesize the available information with general medical knowledge to address common pediatric epilepsy syndromes across age groups.
Neonatal Period (0-29 days)
Clinical Features
- Incidence: 3 per 1,000 live births (higher in preterm: 57-132 per 1,000) 1
- Most Common Etiologies: Hypoxic-ischemic injury (46-65%), intracranial hemorrhage, perinatal stroke (10-12%) 1
- Timing: 90% of HIE-related seizures occur within 2 days of birth; seizures after day 7 suggest infection, genetic disorders, or cortical malformations 1
EEG Requirements
EEG confirmation is mandatory for diagnosis - only focal clonic and focal tonic seizures can be diagnosed clinically; all other seizure types require EEG or amplitude-integrated EEG (aEEG) confirmation 2
Treatment Algorithm
First-Line Therapy:
- Phenobarbital (bolus, repeat once if needed) for all etiologies 2
- Exception: If family history suggests channelopathy (self-limited familial neonatal epilepsy, KCNQ2/KCNQ3 variants), use sodium channel blocker (phenytoin or carbamazepine) as first-line 2
- Critical caveat: Use phenobarbital for shortest duration possible; discontinue early for acute provoked seizures responding to treatment 2
Second-Line Therapy:
- For most etiologies (HIE, stroke, hemorrhage): Phenytoin or levetiracetam 2
- If channelopathy suspected (based on clinical/EEG features): Sodium channel blocker (phenytoin or carbamazepine) 2
- If cardiac disorders present: Levetiracetam preferred 2
- If refractory without identified etiology: Trial of pyridoxine (add-on to ASM), then pyridoxal-5-phosphate if unsuccessful 2
- Less favorable options: Midazolam, lidocaine 2
Discontinuation Strategy: Following cessation of acute provoked seizures without evidence of neonatal-onset epilepsy, discontinue ASM before discharge regardless of MRI or EEG findings 2
Infancy and Early Childhood
Benign Familial Neonatal Convulsions
- Genetics: Autosomal dominant channelopathy (KCNQ2/KCNQ3)
- Prognosis: Favorable with spontaneous resolution 3
Benign Idiopathic Neonatal Seizures ("Fifth-Day Fits")
- Prognosis: Excellent, self-limited 3
West Syndrome (Infantile Spasms)
- Age of Onset: 3-12 months (peak 4-6 months)
- Seizure Type: Epileptic spasms in clusters
- EEG Pattern: Hypsarrhythmia
- Treatment: ACTH or vigabatrin (particularly for tuberous sclerosis)
Childhood (2-12 years)
Benign Rolandic Epilepsy (BRE) - Most Common Pediatric Focal Epilepsy
- Age of Onset: 3-13 years (peak 7-8 years)
- Seizure Type: Focal motor seizures involving face/mouth, often nocturnal
- EEG Pattern: Centrotemporal spikes, potentiated during sleep 4
- Treatment: Many require no treatment; remits by age 16 3, 4
- Prognosis: Excellent, though "benign" label may not apply if cognitive/language delays present 3
Childhood Absence Epilepsy (CAE)
- Age of Onset: 4-8 years
- Seizure Type: Typical absence seizures (brief staring spells)
- EEG Pattern: 3 Hz generalized spike-wave
- Treatment: Ethosuximide or valproic acid as first-line
- Prognosis: ~80% remission rate, but associated learning disorders and poor social outcomes common 5
- Caveat: Not as benign as previously thought due to cognitive comorbidities
Panayiotopoulos Syndrome (Early-Onset Childhood Occipital Epilepsy)
- Age of Onset: 3-6 years
- Seizure Type: Autonomic seizures (vomiting, pallor), often prolonged
- EEG Pattern: Occipital spikes, abundant interictal activity 4
- Treatment: Often self-limited, may not require treatment
- Prognosis: Excellent
Gastaut Type (Late-Onset Childhood Occipital Epilepsy)
- Age of Onset: 7-10 years
- Seizure Type: Visual symptoms, headache
- EEG Pattern: Occipital spikes 4
- Prognosis: Generally favorable
Lennox-Gastaut Syndrome (Catastrophic)
- Age of Onset: 3-5 years
- Seizure Types: Multiple (tonic, atonic/drop attacks, atypical absence)
- EEG Pattern: Slow spike-wave (<2.5 Hz)
- Treatment: Lamotrigine (Level A evidence for drop attacks) 6; valproic acid, rufinamide, clobazam
- Prognosis: Poor developmental outcomes, treatment-resistant 5
Landau-Kleffner Syndrome (Catastrophic)
- Age of Onset: 3-7 years
- Features: Acquired aphasia, behavioral regression
- EEG Pattern: Continuous spike-wave during slow sleep
- Treatment: Inconsistent response to ASMs; consider steroids, IVIG 5
Adolescence (12+ years)
Juvenile Myoclonic Epilepsy (JME)
- Age of Onset: 12-18 years
- Seizure Types: Myoclonic jerks (especially morning), generalized tonic-clonic, absence
- EEG Pattern: 4-6 Hz generalized polyspike-wave
- Treatment: Valproic acid or levetiracetam first-line
- Prognosis: Lifelong condition requiring treatment; excellent seizure control with medication but high relapse rate if discontinued 3
- Triggers: Sleep deprivation, alcohol, photic stimulation
Adjunctive Therapy for Refractory Partial Seizures in Children
Level A Evidence (may be used as adjunctive treatment): Gabapentin (23-35 mg/kg/day), lamotrigine (1-5 mg/kg/day with enzyme inducers; 1-3 mg/kg/day with VPA), oxcarbazepine (30-46 mg/kg/day), topiramate (125-400 mg/day) 6
Important Safety Concerns:
Critical Pitfalls to Avoid
Neonatal seizures: Do not rely on clinical observation alone except for focal clonic/tonic seizures - EEG confirmation is essential 2
Phenobarbital exposure: Minimize duration due to potential adverse neurodevelopmental effects 2
Channelopathies: Recognize family history or characteristic EEG patterns early to guide sodium channel blocker use 2
"Benign" syndromes: Do not assume completely benign course - monitor for cognitive and language comorbidities 3
Gabapentin in generalized epilepsy: May worsen myoclonic seizures 6
Premature ASM discontinuation: For JME, lifelong treatment typically required despite good control 3